Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| S15-H52P7 | Human | Human S1PR5 / EDG8 Full Length Protein (VLP) |
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Fingolimod Hydrochloride | FTY-720A; TDI-132; FTY-720 | Approved | Novartis Pharma Ag | Gilenia, Imusera, 捷灵亚, Gilenya | United States | Multiple Sclerosis | Novartis Pharma Ag | 2010-09-21 | Cerebral Hemorrhage, Traumatic; Amyotrophic Lateral Sclerosis; Uveitis; Asthma; Intracranial Hemorrhage, Hypertensive; Brain Edema; Hypesthesia; Breast Neoplasms; Optic Neuritis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Cerebral Hemorrhage; Renal Insufficiency; Schizophrenia; Rett Syndrome; Pain; Intracranial Hemorrhages; Rejection of renal transplantation; Peripheral Nervous System Diseases; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |
| Ozanimod hydrochloride | CYM-5442; RPC-1063 | Approved | The Scripps Research Institute Inc | 热珀西亚, Zeposia | United States | Multiple Sclerosis | Bristol-Myers Squibb Company | 2020-03-25 | Multiple Sclerosis, Relapsing-Remitting; Digestive System Diseases; Gram-Negative Bacterial Infections; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Liver Diseases; Colitis, Ulcerative; Crohn Disease | Details |
| Etrasimod arginine | APD-334; MXE5EMA09L; APD-334 L-Arginine; PF-07915503 | Approved | Arena Pharmaceuticals Inc | VELSIPITY | United States | Colitis, Ulcerative | Pfizer Inc | 2023-10-12 | Inflammatory Bowel Diseases; Pyoderma Gangrenosum; Alopecia Areata; Intraabdominal Infections; Cholangitis, Sclerosing; Eosinophilic Esophagitis; Colitis, Ulcerative; Dermatitis, Atopic; Eczema; Crohn Disease | Details |
| Fingolimod lauryl sulfate | Approved | Handa Neuroscience LLC | Tascenso ODT | United States | Multiple Sclerosis | Handa Neuroscience LLC | 2021-10-18 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | Details | |
| Siponimod | NVP-BAF312-AEA; BAF-312; NVP-BAF312-NX | Approved | Novartis Pharma Ag | Mayzent | United States | Multiple Sclerosis | Novartis Pharma Ag | 2019-03-26 | Multiple Sclerosis, Relapsing-Remitting; Polymyositis; Cerebral Hemorrhage; Dermatomyositis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Stroke; Hepatic Insufficiency | Details |
This web search service is supported by Google Inc.
A-Z
